The Stanley Foundation Bipolar Network

2. Preliminary summary of demographics, course of illness and response to novel treatments

R. W. Kupka, W. A. Nolen, L. L. Altshuler, K. D. Denicoff, Mark A Frye, G. S. Leverich, Jr Keck P.E., S. L. McElroy, A. J. Rush, T. Suppes, R. M. Post

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. Aims To give a preliminary summary of emerging findings in these areas. Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder. Declaration of interest Support received from the Theodore and Vada Stanley Foundation.

Original languageEnglish (US)
JournalBritish Journal of Psychiatry
Volume178
Issue numberSUPPL. 141
StatePublished - 2001
Externally publishedYes

Fingerprint

Demography
olanzapine
Antimanic Agents
National Institute of Mental Health (U.S.)
Excipients
Bipolar Disorder
Antidepressive Agents
Psychiatry
Comorbidity
Therapeutics
Randomized Controlled Trials
Biomarkers
topiramate
gabapentin
lamotrigine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Kupka, R. W., Nolen, W. A., Altshuler, L. L., Denicoff, K. D., Frye, M. A., Leverich, G. S., ... Post, R. M. (2001). The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments. British Journal of Psychiatry, 178(SUPPL. 141).

The Stanley Foundation Bipolar Network : 2. Preliminary summary of demographics, course of illness and response to novel treatments. / Kupka, R. W.; Nolen, W. A.; Altshuler, L. L.; Denicoff, K. D.; Frye, Mark A; Leverich, G. S.; Keck P.E., Jr; McElroy, S. L.; Rush, A. J.; Suppes, T.; Post, R. M.

In: British Journal of Psychiatry, Vol. 178, No. SUPPL. 141, 2001.

Research output: Contribution to journalArticle

Kupka, RW, Nolen, WA, Altshuler, LL, Denicoff, KD, Frye, MA, Leverich, GS, Keck P.E., J, McElroy, SL, Rush, AJ, Suppes, T & Post, RM 2001, 'The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments', British Journal of Psychiatry, vol. 178, no. SUPPL. 141.
Kupka, R. W. ; Nolen, W. A. ; Altshuler, L. L. ; Denicoff, K. D. ; Frye, Mark A ; Leverich, G. S. ; Keck P.E., Jr ; McElroy, S. L. ; Rush, A. J. ; Suppes, T. ; Post, R. M. / The Stanley Foundation Bipolar Network : 2. Preliminary summary of demographics, course of illness and response to novel treatments. In: British Journal of Psychiatry. 2001 ; Vol. 178, No. SUPPL. 141.
@article{1a1a4b366e044f07a725d7183fafb19f,
title = "The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments",
abstract = "Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. Aims To give a preliminary summary of emerging findings in these areas. Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder. Declaration of interest Support received from the Theodore and Vada Stanley Foundation.",
author = "Kupka, {R. W.} and Nolen, {W. A.} and Altshuler, {L. L.} and Denicoff, {K. D.} and Frye, {Mark A} and Leverich, {G. S.} and {Keck P.E.}, Jr and McElroy, {S. L.} and Rush, {A. J.} and T. Suppes and Post, {R. M.}",
year = "2001",
language = "English (US)",
volume = "178",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "SUPPL. 141",

}

TY - JOUR

T1 - The Stanley Foundation Bipolar Network

T2 - 2. Preliminary summary of demographics, course of illness and response to novel treatments

AU - Kupka, R. W.

AU - Nolen, W. A.

AU - Altshuler, L. L.

AU - Denicoff, K. D.

AU - Frye, Mark A

AU - Leverich, G. S.

AU - Keck P.E., Jr

AU - McElroy, S. L.

AU - Rush, A. J.

AU - Suppes, T.

AU - Post, R. M.

PY - 2001

Y1 - 2001

N2 - Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. Aims To give a preliminary summary of emerging findings in these areas. Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder. Declaration of interest Support received from the Theodore and Vada Stanley Foundation.

AB - Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. Aims To give a preliminary summary of emerging findings in these areas. Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder. Declaration of interest Support received from the Theodore and Vada Stanley Foundation.

UR - http://www.scopus.com/inward/record.url?scp=17144444629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144444629&partnerID=8YFLogxK

M3 - Article

VL - 178

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - SUPPL. 141

ER -